6533b82bfe1ef96bd128e2fa
RESEARCH PRODUCT
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations
Steven Le GouillJan WalewskiPier Luigi ZinzaniMarek TrněnýFrancesco ZajaCarlo ViscoMartin DreylingIgor AurerGeorg HessOlivier HermineVincent RibragMats JerkemanSergio Cortelazzosubject
OncologyCancer ResearchLymphomaDrug ResistanceLymphoma Mantle-Cell[ SDV.CAN ] Life Sciences [q-bio]/Cancerchemistry.chemical_compound0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMedicineChemotherapy ; clinical trials ; mantle cell lymphoma ; molecular targeted therapyBortezomibCombination chemotherapyclinical trialChemotherapy; clinical trials; mantle cell lymphoma; molecular targeted therapy; Hematology; Oncology; Cancer ResearchHematologyTemsirolimusEuropeLocalOncology030220 oncology & carcinogenesisIbrutinibPractice Guidelines as TopicRituximabRituximabmedicine.drugmedicine.medical_specialtymolecular targeted therapymantle cell lymphoma03 medical and health sciencesClinical Trials Phase II as TopicInternal medicineHumansChemotherapyLenalidomideclinical trialsbusiness.industryPhase II as TopicMantle-Cellmedicine.diseaseClinical trialChemotherapy; clinical trials; mantle cell lymphoma; molecular targeted therapy; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials Phase II as Topic; Drug Resistance Neoplasm; Europe; Humans; Lymphoma Mantle-Cell; Neoplasm Recurrence Local; Practice Guidelines as Topic; RituximabNeoplasm RecurrencechemistryDrug Resistance NeoplasmNeoplasmMantle cell lymphomaNeoplasm Recurrence Localbusiness030215 immunologydescription
International audience; Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy, but the disease inevitably relapses and often follows an aggressive course. Here, clinical study results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare available evidence for treatment guidance. Most trials identified were non-randomized, phase II studies performed at a limited number of sites, and many evaluated MCL as one of multiple non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed. Treatment selection generally depends on patient need, age and fitness, time of relapse, and line of therapy. Combination regimens typically produce higher response rates than single agents, and adding rituximab generally improves outcomes. The inclusion of ibrutinib, lenalidomide, temsirolimus, and bortezomib, represents an important advance for patients ineligible for, unable to tolerate, or failing high-intensity combination chemotherapy. A high need for effective treatments in relapsed/refractory MCL remains, particularly for elderly and frail patients.
year | journal | country | edition | language |
---|---|---|---|---|
2017-11-27 |